Key Takeaways
- • UNC Health has relaunched its venture capital fund as UNC Health Ventures with $125 million in capital, succeeding Rex Health Ventures, which operated for 14 years with $10 million in initial seed funding.
- • The predecessor fund backed nearly 30 early-stage healthcare companies and deployed more than half of its capital in active companies, with returns exceeding total investments, though specific fund performance figures were not disclosed.
- • Capital is sourced from UNC Health's broader investment portfolio, with income reinvested to support patient care, operations, and research, signaling a strategic shift toward earlier-stage technology engagement.
- • The fund's dual mandate targets startups developing equipment or therapies that benefit local patients while generating financial returns and creating regional jobs across UNC Health's 20-hospital, multi-clinic network in North Carolina.
- • Recent portfolio success includes Reprieve Cardiovascular, a heart failure technology company that raised $61 million in 2025 with Rex's backing and has begun patient enrollment in clinical trials.
Summary
UNC Health, a nonprofit health system operating 20 hospitals and hundreds of clinics across North Carolina, has formally relaunched its venture capital arm with $125 million in committed capital. The new fund, UNC Health Ventures, replaces Rex Health Ventures, a 14-year-old investment vehicle created in 2012 with $10 million in seed funding. The relaunch represents a strategic recapitalization and repositioning aimed at engaging with emerging healthcare technologies at earlier stages of development.
Funding for the new vehicle is drawn from UNC Health's broader investment portfolio, with all income reinvested into patient care, operations, and research. Spokesman Alan Wolf noted that the predecessor fund's returns exceeded its total investments, with more than half of capital remaining deployed in active portfolio companies—indicating strong underlying performance, though specific return metrics were not disclosed. Over its 14-year lifecycle, Rex Health Ventures backed nearly 30 early-stage companies while pursuing a three-pronged mission of financial returns, healthcare innovation, and local job creation.
The fund operates under a dual-benefit investment model targeting startups developing equipment or therapies that address clinical needs for UNC Health patients while simultaneously delivering financial returns. This approach aligns the health system's clinical and financial objectives. Cristy Page, UNC Health's chief executive officer and dean of the UNC School of Medicine, emphasized the rationale: "Novel technologies are essential to advancing the care we provide to our patients and communities."
A notable portfolio success demonstrates the fund's track record: Reprieve Cardiovascular, a Massachusetts-based medtech company developing heart failure treatment technology, raised $61 million in 2025 with Rex Health Ventures as a participating investor and has since begun patient enrollment in clinical trials. This outcome illustrates the fund's ability to back companies that progress from early investment to clinical validation and capital scaling.
Funding for the new vehicle is drawn from UNC Health's broader investment portfolio, with all income reinvested into patient care, operations, and research. Spokesman Alan Wolf noted that the predecessor fund's returns exceeded its total investments, with more than half of capital remaining deployed in active portfolio companies—indicating strong underlying performance, though specific return metrics were not disclosed. Over its 14-year lifecycle, Rex Health Ventures backed nearly 30 early-stage companies while pursuing a three-pronged mission of financial returns, healthcare innovation, and local job creation.
The fund operates under a dual-benefit investment model targeting startups developing equipment or therapies that address clinical needs for UNC Health patients while simultaneously delivering financial returns. This approach aligns the health system's clinical and financial objectives. Cristy Page, UNC Health's chief executive officer and dean of the UNC School of Medicine, emphasized the rationale: "Novel technologies are essential to advancing the care we provide to our patients and communities."
A notable portfolio success demonstrates the fund's track record: Reprieve Cardiovascular, a Massachusetts-based medtech company developing heart failure treatment technology, raised $61 million in 2025 with Rex Health Ventures as a participating investor and has since begun patient enrollment in clinical trials. This outcome illustrates the fund's ability to back companies that progress from early investment to clinical validation and capital scaling.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.